Biofrontera Inc. Files S-1 with SEC
Ticker: BFRIW · Form: S-1 · Filed: Jan 17, 2025 · CIK: 1858685
Sentiment: neutral
Topics: sec-filing, s-1, bio-pharma
TL;DR
Biofrontera filed an S-1, check financials for 2022-2024.
AI Summary
Biofrontera Inc. filed an S-1 form on January 21, 2025, detailing its financial status. The company, incorporated in Delaware with its principal office in Woburn, MA, operates in the pharmaceutical preparations sector. Key financial periods reported include fiscal years ending December 31, 2022, and 2023, and the nine months ending September 30, 2024.
Why It Matters
This S-1 filing provides crucial financial and operational details for Biofrontera Inc., offering insights into its performance and strategic direction for investors and the market.
Risk Assessment
Risk Level: medium — S-1 filings are standard for companies going public or making significant changes, but the specific details within this filing will determine the actual risk level.
Key Numbers
- 2024-09-30 — Nine Months Ended (Financial reporting period)
- 2023-12-31 — Fiscal Year End (Financial reporting period)
- 2022-12-31 — Fiscal Year End (Financial reporting period)
Key Players & Entities
- Biofrontera Inc. (company) — Filer of the S-1 form
- 0001493152-25-002844 (document_id) — Accession number for the filing
- 20250121 (date) — Filing date
- 20250117 (date) — Date as of which the filing is made
- 0001858685 (company_id) — Central Index Key for Biofrontera Inc.
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- DE (state) — State of incorporation
- 1231 (fiscal_year_end) — Fiscal year end date
- 333-284371 (sec_file_number) — SEC file number for the registration
- WOBURN (city) — Business and mailing address city
FAQ
What is the primary purpose of this S-1 filing for Biofrontera Inc.?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, indicating potential future offerings or significant corporate actions.
What industry does Biofrontera Inc. operate in?
Biofrontera Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code 2834.
When was Biofrontera Inc. incorporated and where is its principal office located?
Biofrontera Inc. was incorporated in Delaware (DE) and its principal business address is in Woburn, MA.
What are the key fiscal periods covered by the financial data in this filing?
The filing references financial data for the nine months ended September 30, 2024, and the full fiscal years ending December 31, 2023, and December 31, 2022.
What is the SEC file number associated with this Biofrontera Inc. S-1 filing?
The SEC file number for this registration statement is 333-284371.
Filing Stats: 4,559 words · 18 min read · ~15 pages · Grade level 13.4 · Accepted 2025-01-21 09:24:21
Key Financial Figures
- $0.001 — up to 5,716,927 shares of common stock, $0.001 par value per share ("common stock"), c
- $1.07 — price per share of our common stock was $1.07. The Selling Stockholders will offer
- $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
- $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
- $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
- $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
- $346 — $400 million, assuming a tube price of $346). 6 1 Fuchs & Marmur, Dermatol Surg.
Filing Documents
- forms-1.htm (S-1) — 3386KB
- ex5-1.htm (EX-5.1) — 29KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 34KB
- forms-1_001.jpg (GRAPHIC) — 4KB
- forms-1_002.jpg (GRAPHIC) — 3KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-002844.txt ( ) — 13086KB
- bfri-20240930.xsd (EX-101.SCH) — 94KB
- bfri-20240930_cal.xml (EX-101.CAL) — 112KB
- bfri-20240930_def.xml (EX-101.DEF) — 387KB
- bfri-20240930_lab.xml (EX-101.LAB) — 637KB
- bfri-20240930_pre.xml (EX-101.PRE) — 547KB
- forms-1_htm.xml (XML) — 2047KB
RISK FACTORS
RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 44
USE OF PROCEEDS
USE OF PROCEEDS 45 DIVIDEND POLICY 45
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 46
BUSINESS
BUSINESS 65 MANAGEMENT 77
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 82 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 87
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 89
DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION
DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 90 PRIVATE PLACEMENT OF THE NOTES 99 SELLING STOCKHOLDERS 100 PLAN OF DISTRIBUTION 101 LEGAL MATTERS 103 EXPERTS 103 WHERE YOU CAN FIND MORE INFORMATION 103 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS We and the Selling Stockholders have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We and the Selling Stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We and the Selling Stockholders have not done anything that would permit the sale of our common stock being offered by the Selling Stockholders in any jurisdiction where action for that purpose is required, other than in the United relating to, the offering of the shares and the distribution of this prospectus outside the United States . BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to "we," "us," "our," the "Company," "Biofrontera" and similar references refer to Biofrontera Inc. which includes its wholly owned subsidiary Biofrontera Discovery GmbH. References in this prospectus to the " Biofrontera Group " (a related party) refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pharma GmbH (individually, "Biofrontera Pharma" ), Biofrontera Bioscience GmbH
Risk Factors
Risk Factors Investing in our common stock involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading "Risk Factors" included elsewhere in this prospectus may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks include the following: Currently, our sole source of revenue is from sales of products we license from other companies. If we fail to comply with our obligations in the agreements under which we license rights from such third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business. Certain important patents for our licensed product Ameluz expired in 2019. Although the process of developing generic topical dermatological products for the first time presents specific challenges that may deter potential generic competitors, generic versions of Ameluz may enter the market following the recent expiration of these patents. If this happens, we may need to reduce the price of Ameluz significantly and may lose significant market share. Our business depends substantially on the success of our principal licensed product Ameluz . If the Ameluz Licensor is unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz for existing and additional indications, our business may be materially harmed. The Ameluz Licensor currently depends on a single unaffiliated contract manufacturer to manufacture Ameluz and has recently contracted with a second unaffiliated contract manufacturer to begin producing Ameluz . If the Ameluz Licensor fails to maintain its relationships with these manufacturers or if both of these manufacturers are unable to produce product for the Ameluz Licensor, our business could be materially harmed. If our Licensors or our Lice